Roth/MKM lowers IMAX stock price target on China headwinds By Investing.com

The clean read is that IMAX is still a share-gain story, but the market is now paying up for a path that is increasingly dependent on the back half of the year. That creates a timing mismatch: the equity can stay supported on upgraded industry confidence, yet the next leg higher likely needs proof that non-China demand can absorb a softer China comp set without margin giveback. In other words, the stock is less about absolute box office and more about whether the company can keep monetizing premium formats at a faster rate than the consensus is modeling.

The second-order winner is the broader premium theatrical ecosystem: exhibitors with format exposure, content owners with tentpole slates, and licensors that benefit from higher per-screen economics. The loser is anyone implicitly anchored to China as the primary growth engine, because this setup is making the business look more geographically diversified while simultaneously reminding investors that one region can still dominate quarterly variance. That usually compresses the multiple only when the market stops believing the diversification story; until then, the valuation premium can persist longer than fundamentals suggest.

The governance overhang is a real but currently underpriced catalyst risk. Management absence matters less for day-to-day operations than for signaling during a period when investors are underwriting a multi-quarter acceleration; any delay in commentary, guidance confidence, or event participation can widen the discount rate applied to a richly priced name. The contrarian view is that consensus may be overfocusing on the raised target prices and underestimating how much of the 2026 narrative is already embedded in a stock trading on expectations of continued market-share gains rather than near-term earnings delivery.